ADC 1013

Drug Profile

ADC 1013

Alternative Names: ADC-1013; ADC-1013 (agonistic immunostimulatory antibody); JNJ-64457107

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Alligator Bioscience
  • Developer Alligator Bioscience; Janssen Biotech
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD40 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Sep 2016 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (IV, Infusion)
  • 07 Jul 2016 Janssen Research & Development plans a phase I trial for Solid tumours (Late-stage disease) in USA (IV, Infusion) (NCT02829099)
  • 12 Aug 2015 ADC 1013 licensed to Janssen biotech worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top